A recent population-based retrospective cohort study comprehensively evaluated the rates of adverse events (AEs) involving cerebral thromboembolism (CTE) after administration of COVID-19 vaccines. This study, conducted with meticulousness and scientific rigor, used data collected from the VAERS (Vaccine Adverse Event Reporting System) database of the US Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) since 1 January 1990 to December 31, 2023, offering a detailed and temporal picture of the adverse events reported. The results of this study are particularly alarming in light of growing concerns regarding the safety of COVID-19 vaccinesand raise crucial questions about the long-term implications of mass vaccination in response to the global pandemic.
Covid-19 Vaccines and Cerebral Thromboembolism
The VAERS database, a key resource for collecting data on post-vaccination adverse events, was used to systematically and detailedly collect data on adverse events reported in relation to vaccines COVID-19, flu vaccines and all other vaccines. Cerebral thromboembolism (CTE) adverse events reported after COVID-19 vaccination were compared to those after influenza vaccines and all other vaccines using time-based proportional reporting ratio (PRR) analysis.
This advanced methodology allows you to identify any significant differences in AE reporting rates between different groups of vaccines, thus allowing you to isolate and better understand the specific risks associated with each type of vaccine. The detailed analysis of PRRwith confidence intervals and p-values, offers a clear and scientifically robust picture of relative risks, providing a solid basis for policy and health decisions.
The increase in cases of Cerebral Thromboembolism
In the 36 month period following the vaccination against COVID-19, a total of 5,137 adverse events of cerebral thromboembolism were reported. This is significantly higher than the 52 adverse events reported for influenza vaccines over the past 34 years (408 months) and the 282 adverse events reported for all other vaccines (excluding influenza vaccines) over the same 34-year period .
PRRs are found to be highly significant when comparing adverse events associated with COVID-19 vaccines with those of influenza vaccines (p
These data indicate a significantly greater risk of cerebral thromboembolism associated with COVID-19 vaccines compared to the other vaccines consideredraising serious concerns about the safety of these vaccines and the need for a thorough review of vaccination policies.
Gender differences and type of thromboembolism
The detailed analysis also revealed that adverse events related to cerebral venous thromboembolism are predominantly female, with a female/male odds ratio of 1.63 (95% confidence interval (1.52-1.74), p vulnerability greater in women than men, requiring further research to understand the underlying mechanisms of this gender difference.
In reverse, cerebral arterial thromboembolism showed a non-significant preponderance in gender male, indicating that risk may be more balanced or influenced by other factors not yet fully understood. Furthermore, cerebral venous thromboembolism was significantly more common than cerebral arterial thromboembolism over 36 months, with an odds ratio (OR) of 14.8 (95% CI 14.0-15.5, p
This suggests that, although both types of thromboembolism are of concern, the risk of venous events is significantly higher, requiring targeted interventions to mitigate this specific risk.
Atrial fibrillation and cerebral thromboembolism
Another critical aspect that emerged from the study is the correlation between atrial fibrillation and cerebral thromboembolism.
Atrial fibrillation, identified as the most common cause of cerebral venous thromboembolism, was found to be much more frequent after vaccination against COVID-19 than after all other vaccines, with a PRR of 123 (95% CI 88.3-172 , p
This data indicates a worrying correlation between the administration of the COVID-19 vaccine and the onset of atrial fibrillation, which in turn increases the risk of cerebral thromboembolic events. Atrial fibrillation is a serious cardiac condition that can lead to serious complications, and its association with COVID-19 vaccination requires urgent attention and further studies to better understand the mechanisms involved and develop strategies to mitigate this risk.
Alarming conclusions on Covid-19 vaccines
The conclusions of the study point to one alarming violation of the safety signal threshold regarding adverse events related to cerebral thrombosis after administration of COVID-19 vaccines. Comparisons with influenza vaccines and all other vaccines revealed a significantly higher risk of cerebral thromboembolism associated with COVID-19 vaccines.
As a result, the study authors recommend a “immediate global moratorium on the use of COVID-19 vaccines, with a absolute contraindication for women of reproductive age“. These recommendations are based on data that highlight not only an increased risk of cerebral thromboembolism, but also a greater prevalence of atrial fibrillation after vaccination against COVID-19, factors that together pose a significant threat to public health. The authors suggest that global health agencies and governments take these findings seriously and take immediate measures to protect the population by carefully weighing the benefits and risks of COVID-19 vaccines.
Continue reading on MeteoWeb
